Adagio is a clinical-stage biopharmaceutical company focusing on the discovery and development of antibody-based solutions for infectious diseases with pandemic potential. It develops ADG20 for the treatment and prevention of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. Its portfolio includes non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company also researches additional neutralizing antibodies, such as ADG10, for potential use in combination with ADG20.